Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma

被引：0
|
作者：
Mora, Jaume
Chan, Godfrey C.
Morgenstern, Daniel A.
Amoroso, Loredana
Nysom, Karsten
Faber, Joerg
Wingerter, Arthur
Bear, Melissa
Rubio-San-Simon, Alba
Tornoe, Karen
Duering, Maria
Kushner, Brian H.
机构：
[1] Hosp St Joan de Deu, Pediat Canc Ctr Barcelona, Barcelona, Spain
[2] Queen Mary Hosp, Hong Kong, Peoples R China
[3] Univ Hong Kong, Hong Kong Childrens Hosp, Pokfulam, Hong Kong, Peoples R China
[4] Hosp Sick Children, Toronto, ON, Canada
[5] IRCCS Ist Giannina Gaslini, Genoa, Italy
[6] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[7] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Pediat & Adolescent Med, Mainz, Germany
[8] Riley Hosp Children, Indianapolis, IN USA
[9] Hosp Infantil Univ Nino Jesus, Madrid, Spain
[10] Y mAbs AS, Horsholm, Denmark
[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10033
引用
收藏
页数：1
相关论文
共 50 条
  • [41] DFMO Maintains Remission in Relapsed/Refractory High Risk Neuroblastoma
    Sholler, Giselle Saulnier
    Ferguson, William
    Bergendahl, Genevieve
    Bond, Jeffrey
    Neville, Kathleen
    Eslin, Don
    Brown, Valerie
    Roberts, William
    Wada, Randy
    Oesterheld, Javier
    Mitchell, Deanna
    Foley, Jessica
    Zage, Peter
    Rawwas, Jawhar
    Sencer, Susan
    Kraveka, Jacqueline
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S46 - S47
  • [42] Naxitamab-Based Chemoimmunotherapy for Resistant High-Risk Neuroblastoma: Preliminary Results of Hits Treatment
    Mora, J.
    Castaneda, A.
    Flores, M.
    Gorostegui, M.
    Simao, M.
    Santa-Maria, V.
    Garraus, M.
    Chamizo, A.
    Lazaro, J. J.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S32 - S32
  • [43] Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience
    Olgun, N.
    Cecen, R. E.
    Ince, D.
    Onal, A.
    Baysal, B.
    Akyol, S.
    Ozdogan, O.
    Guleryuz, H.
    Aktas, S.
    Ozer, E.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S215 - S215
  • [44] Renal toxicity in paediatric patients with high-risk neuroblastoma treated with radiotherapy
    Gomis Selles, E.
    Burgueno Caballero, A. M.
    Munoz Munoz, O.
    Delgado Leon, B. D.
    Cabrera Roldan, P.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1220 - S1222
  • [45] Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.
    Moerdler, Scott
    Naranjo, Arlene
    Tenney, Sheena
    Bagatell, Rochelle
    Yu, Alice L.
    London, Wendy B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
    Metzeler, Klaus H.
    Winer, Eric S.
    Platzbecker, Uwe
    Verma, Amit
    DeAngelo, Daniel J.
    Tarantolo, Stefano R.
    Sallman, David A.
    Dugan, James
    Groepper, Stefanie
    Goetze, Katharina S.
    Li, Chia-Cheng
    Zhao, Wanying
    Lane, Maureen
    von Roemeling, Reinhard
    Carlisle, Samantha
    Weigert, Anne
    Boehme, Matthias
    Kubasch, Anne Sophie
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 9048 - 9049
  • [47] Naxitamab and GM-CSF for consolidation of high-risk neuroblastoma (HR-NB) patients in complete remission.
    Mora, Jaume
    Castaneda, Alicia
    Perez-Jaume, Sara
    Gorostegui, Maite
    Santa-Maria, Vicente
    Pablo Munoz, Juan
    Varo, Amalia
    Mane, Salvador
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
    Siebert, Nikolai
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Zumpe, Maxi
    Wegner, Danilo
    Kietz, Silke
    Ehlert, Karoline
    Veal, Gareth J.
    Siegmund, Werner
    Weiss, Michael
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    MABS, 2016, 8 (03) : 604 - 616
  • [49] THE IMPACT OF POST-INDUCTION TREATMENT ON RESPONSE AND OUTCOMES OF PATIENTS WITH HIGH-RISK NEUROBLASTOMA WITH REFRACTORY DISEASE.
    Siddiqui, A.
    Desai, A.
    Cohn, S.
    Gao, G.
    Oppong, A.
    Yuan, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S52 - S52
  • [50] Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
    Olgun, Nur
    Cecen, Emre
    Ince, Dilek
    Kizmazoglu, Deniz
    Baysal, Birsen
    Onal, Ayse
    Ozdogan, Ozhan
    Guleryuz, Handan
    Cetingoz, Riza
    Demiral, Ayse
    Olguner, Mustafa
    Celik, Ahmet
    Kamer, Serra
    Ozer, Erdener
    Altun, Zekiye
    Aktas, Safiye
    FRONTIERS IN ONCOLOGY, 2022, 12
12345